Literature DB >> 23305474

Multidimensional analysis of clinical symptoms in patients with Fabry's disease.

P Kaminsky1, E Noel, R Jaussaud, V Leguy-Seguin, E Hachulla, T Zenone, C Lavigne, I Marie, F Maillot, A Masseau, C Serratrice, O Lidove.   

Abstract

AIM: Fabry's disease is an X-linked inherited lysosomal storage disorder caused by the deficient activity of alpha-galactosidase A. The interrelationships between clinical symptoms in Fabry patients have not yet been fully established. Using cluster and multivariate analysis, the aim of the study was to determine the relationships among clinical symptoms and organ involvement, and predictive clinical symptoms for disease severity.
METHODS: Clinical data obtained from 108 French Fabry patients were retrospectively collected and analysed using multiple correspondence analysis and hierachical ascendant classification. Multivariate analysis was also performed to determine among clinical symptoms predictors for cardiac disease (HRT), renal involvement (KDN) and brain complication (STR).
RESULTS: The cohort comprised 41 male patients (aged 28.9 ± 11.6 years) and 67 female patients (aged 40.4 ± 15.5 years). Three main clusters of clinical symptoms could be delineated, characterising disease progression: the first cluster grouped digestive disorders (found in 30% of the patients) and exercise intolerance (32%), the second, cluster dyshidrosis (47%), acroparesthesia (67%), angiokeratoma (44%) and cornea verticillata (54%), the third, cluster grouped KDN (30%), HRT (39%) and STR (25%) and hearing loss (44%). In univariate analysis, the patient age predicted HRT and KDN, dyshidrosis predicted HRT and STR, angiokeratoma predicted KDN and cornea verticilla and hearing loss predicted KDN, HRT and STR. In multivariate analysis, hearing loss and age were independent predictors of organ complication.
CONCLUSION: Among the various interrelated clinical symptoms occurring in Fabry disease, patients with dyshidrosis and particularly hearing disorders appear to be at higher risk of organ complications.
© 2013 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23305474     DOI: 10.1111/ijcp.12016

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  4 in total

1.  Hearing loss in adult patients with Fabry disease treated with enzyme replacement therapy.

Authors:  Eefje B Suntjens; Bouwien E Smid; Marieke Biegstraaten; Wouter A Dreschler; Carla E M Hollak; Gabor E Linthorst
Journal:  J Inherit Metab Dis       Date:  2014-11-14       Impact factor: 4.982

2.  Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease.

Authors:  Karen M Ashe; Eva Budman; Dinesh S Bangari; Craig S Siegel; Jennifer B Nietupski; Bing Wang; Robert J Desnick; Ronald K Scheule; John P Leonard; Seng H Cheng; John Marshall
Journal:  Mol Med       Date:  2015-04-30       Impact factor: 6.354

3.  Cardiac device implantation in Fabry disease: A retrospective monocentric study.

Authors:  Thomas Sené; Olivier Lidove; Joel Sebbah; Jean-Marc Darondel; Hervé Picard; Laurent Aaron; Olivier Fain; Thierry Zenone; Dominique Joly; Philippe Charron; Jean-Marc Ziza
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

4.  Fabry Disease With Concomitant Lewy Body Disease.

Authors:  Kelly Del Tredici; Albert C Ludolph; Simone Feldengut; Christian Jacob; Heinz Reichmann; Jürgen R Bohl; Heiko Braak
Journal:  J Neuropathol Exp Neurol       Date:  2020-04-01       Impact factor: 3.685

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.